IBRX
HEALTHCAREImmunitybio Inc
AI Insight
What's Moving IBRX Today?
No stock-specific AI insight has been generated for IBRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.95$12.43
$7.32
Fundamentals
Market Cap$7.7B
P/E Ratio—
EPS$-0.85
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume11.3M
Avg Volume (10D)—
Shares Outstanding1.05B
IBRX News
70 articles- Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a CallerYahoo Finance·Jun 19, 2026
- ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026Yahoo Finance·Jun 11, 2026
- 3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings GrowthYahoo Finance·Jun 8, 2026
- ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy NowYahoo Finance·Jun 6, 2026
- ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer OutlookYahoo Finance·Jun 3, 2026
- ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026Yahoo Finance·Jun 1, 2026
- IBRX Stock Outlook After Q1 Results and a New FDA ReviewYahoo Finance·May 29, 2026
- ImmunityBio: Anktiva Explained and What Comes NextYahoo Finance·May 29, 2026
- ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200Yahoo Finance·May 29, 2026
- ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX)Yahoo Finance·May 28, 2026
- Is ImmunityBio Inc. (IBRX) One of the Best Momentum Stocks to Buy According to Analysts?Yahoo Finance·May 28, 2026
- ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswire·May 22, 2026
- IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s FindingsStocktwits·May 22, 2026
- ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder PreservationYahoo Finance·May 22, 2026
- ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CISYahoo Finance·May 22, 2026
- Assessing ImmunityBio (IBRX) Valuation After FDA Approval For Anktiva And Share Price CooldownYahoo Finance·May 20, 2026
- Why ImmunityBio Stock is Soaring Higher TodayMotley Fool·May 20, 2026
- FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer TherapyYahoo Finance·May 20, 2026
- Exchange-Traded Funds, Equity Futures Advance Pre-Bell Wednesday Ahead of Nvidia Earnings ReportYahoo Finance·May 20, 2026
- ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMorningstar·May 20, 2026
- ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027Yahoo Finance·May 20, 2026
- ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder CancerYahoo Finance·May 19, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire·May 17, 2026
- ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesBusiness Wire·May 16, 2026
- IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026www.marketscreener.com·May 13, 2026
- Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan FoxThe Globe and Mail·May 7, 2026
- IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoilMSN·May 7, 2026
- IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·May 1, 2026
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 29, 2026
- Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 29, 2026
- INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 28, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc.·Apr 28, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 26, 2026
- ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff DeadlineGlobeNewswire Inc.·Apr 25, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc.·Apr 25, 2026
- IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitGlobeNewswire Inc.·Apr 25, 2026
- IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens BermanGlobeNewswire Inc.·Apr 23, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 22, 2026
- Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 22, 2026
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 22, 2026
Price Data
Open$7.05
Previous Close$7.22
Day High$7.60
Day Low$7.00
52 Week High$12.43
52 Week Low$1.95
52-Week Range
$1.95$12.43
$7.32
Fundamentals
Market Cap$7.7B
P/E Ratio—
EPS$-0.85
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume11.3M
Avg Volume (10D)—
Shares Outstanding1.05B
About Immunitybio Inc
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—